{"id":"NCT02222493","sponsor":"Pfizer","briefTitle":"A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).","officialTitle":"A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-26","primaryCompletion":"2016-06-29","completion":"2017-06-01","firstPosted":"2014-08-21","resultsPosted":"2017-09-11","lastUpdate":"2018-05-30"},"enrollment":650,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"PF-06438179","otherNames":["Infliximab-Pfizer"]},{"type":"BIOLOGICAL","name":"Infliximab","otherNames":["Infliximab-EU, Remicade"]}],"arms":[{"label":"PF-06438179","type":"EXPERIMENTAL"},{"label":"Infliximab","type":"ACTIVE_COMPARATOR"}],"summary":"The study will assess the efficacy and safety of PF-06438179 and infliximab in combination with methotrexate in subjects with active rheumatoid arthritis who have had an inadequate response to methotrexate.","primaryOutcome":{"measure":"Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1","timeFrame":"Week 14","effectByArm":[{"arm":"Period 1: PF-06438179","deltaMin":198,"sd":null},{"arm":"Period 1: Infliximab-EU Remicade (INX)","deltaMin":207,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":184,"countries":["United States","Australia","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Czechia","Georgia","Germany","Guatemala","Hungary","Israel","Japan","Jordan","Lithuania","Mexico","Morocco","Peru","Philippines","Poland","Romania","Russia","Serbia","South Africa","South Korea","Tunisia","Ukraine","United Kingdom"]},"refs":{"pmids":["36180101","31939063","31284794","30997153","30053896"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B5371002&StudyName=A%20Study%20of%20PF-06438179%20%28Infliximab-Pfizer%29%20and%20Infliximab%20in%20Combination%20with%20Methotrexate%20in%20Subjects%20with%20Active%20Rheumatoid%20Arthritis%20"]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":323},"commonTop":["Infusion related reaction","Alanine aminotransferase increased"]}}